A Phase 4 interventional study of Immunoglobulin G and Acetylsalicylic acid in Kawasaki Disease, sponsored by Green Cross Corporation. Completed at 7 sites in Korea, Republic of. Open to participants aged 3 Months to 12 Years. Per ClinicalTrials.gov, last updated 2020-05-21.
Sponsored by Green Cross Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy and safety of high-dose human Immunoglobulin G Intravenous (IGIV) 10% in subjects with Kawasaki diseases (KD).
This is a multicenter, single-arm, and open-label clinical trial to evaluate the coronary artery lesions (CALs) at 2 and 7 weeks after single dose of IGIV 10% (2 g/kg) administration for at least 12 hours to evaluate the efficacy and safety of IGIV 10%.
62 studies on the registry are indexed under Mucocutaneous Lymph Node Syndrome; 17 are open to participants now.
This study's enrollment of 45 is close to the median of 45 across 33 interventional studies indexed under Mucocutaneous Lymph Node Syndrome.
Browse Mucocutaneous Lymph Node Syndrome studies →Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with fever 4-10 days meeting one of following criteria (A, B or C)
A. Subjects with at least 4 of the following principal clinical findings:
i) Bilateral bulbar conjunctival injection without exudate
ii) Erythema and cracking of lips, strawberry tongue, and/or erythema of oral and pharyngeal mucosa
iii) Erythema and edema of the hands and feet in acute phase and/or periungual desquamation in subacute phase
iv) Cervical lymphadenopathy (≥1.5 cm diameter), usually unilateral
v) Rash: maculopapular, diffuse erythroderma, or erythema multiforme-like
B. Subjects with at least 3 of the principal clinical findings and coronary artery abnormalities detected by 2-dimensional echocardiography: Z score of left anterior descending coronary artery or right coronary artery ≥2.5
C. Subjects without coronary artery abnormalities, but with fever ≥5 days, 2 or 3 of the principal clinical findings , CRP of ≥3.0 mg/dL and meeting 3 or more of the following laboratory findings:
i) Albumin \<3.0 g/dL
ii) Anemia for age
iii) Elevated level
iv) count of >450,000/mm3 after the 7th day of fever
v) White blood cell count of >15,000/mm3
vi) Urine >10 white blood cells/high-power field
Exclusion Criteria:
Subjects with following laboratory findings:
A. count \<100,000/mm3
B. WBC count \<3,000 cells/mm3
C. , hematocrit or red blood cell count more than 30% above the upper limit or 30% below the lower limit of the normal range
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational product (IP)
Drug: Immunoglobulin G · Drug: Acetylsalicylic acid
single dose of IGIV 10% (2 g/kg) administered intravenously for at least 12 hours
Coadministration
incidence of CALs
incidence of CALs at 7 weeks after treatment
Time frame: 7 weeks
incidence of CALs
incidence of CALs at 2 weeks after treatment
Time frame: 2 weeks
total duration of fever
total duration of fever after treatment
Time frame: baseline
laboratory measurements : markers of inflammation and cardiovascular disease
measurement of erythrocyte sedimentation rate (ESR)
Time frame: 7 weeks
laboratory measurements : markers of inflammation and cardiovascular disease
measurement of C-reactive protein (CRP)
Time frame: 7 weeks
laboratory measurements : markers of inflammation and cardiovascular disease
measurement of N-terminal pro B-type natriuretic peptide (NTproBNP) or B-type natriuretic peptide (BNP)
Time frame: 7 weeks
laboratory measurements : markers of inflammation and cardiovascular disease
measurement of creatine kinase-myocardial band (CK-MB)
Time frame: 7 weeks
laboratory measurements : markers of inflammation and cardiovascular disease
measurement of procalcitonin
Time frame: 7 weeks
laboratory measurements : markers of inflammation and cardiovascular disease
measurement of soluble suppression of tumorigenicity 2 (sST2)
Time frame: 7 weeks
laboratory measurements : markers of inflammation and cardiovascular disease
measurement of Troponin I
Time frame: 7 weeks
IGIV resistance
frequency of IGIV resistance
Time frame: baseline
adverse events, adverse drug reactions and serious adverse events
number of adverse events, adverse drug reactions and serious adverse events
Time frame: 7 weeks
laboratory measurements : hematological parameters
measurement of white blood cell (WBC)
Time frame: 7 weeks
laboratory measurements : hematological parameters
measurement of red blood cell (RBC)
Time frame: 7 weeks
laboratory measurements : hematological parameters
measurement of hemoglobin
Time frame: 7 weeks
laboratory measurements : hematological parameters
measurement of hematocrit
Time frame: 7 weeks
laboratory measurements : hematological parameters
measurement of platelet count
Time frame: 7 weeks
laboratory measurements : clinical chemistry parameters
measurement of alanine transaminase (ALT)
Time frame: 7 weeks
laboratory measurements : clinical chemistry parameters
measurement of albumin
Time frame: 7 weeks
laboratory measurements : urinalysis
measurement of WBC (urine microscopy)
Time frame: 7 weeks
vital signs: blood pressure
measurement of systolic and diastolic blood pressure
Time frame: 7 weeks
vital signs: body temperature
measurement of body temperature
Time frame: 7 weeks
physical examination
visual inspection of general appearance, head, eyes, nose-mouth-throat, lymph nodes, skin, extremities for abnormal findings
Time frame: 7 weeks
Ran from Feb 2019 to primary completion in Nov 2019, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin
Mucocutaneous Lymph Node Syndrome →